- Home
- NG vs TVTX Comparison
NG vs TVTX Comparison
Compare NG & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NG
- TVTX
- Stock Information
- Founded
- NG 1984
- TVTX 2008
- Country
- NG Canada
- TVTX United States
- Employees
- NG N/A
- TVTX N/A
- Industry
- NG Precious Metals
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- NG Basic Materials
- TVTX Health Care
- Exchange
- NG Nasdaq
- TVTX Nasdaq
- Market Cap
- NG 1.2B
- TVTX 1.3B
- IPO Year
- NG N/A
- TVTX N/A
- Fundamental
- Price
- NG $3.40
- TVTX $17.72
- Analyst Decision
- NG
- TVTX Buy
- Analyst Count
- NG 0
- TVTX 13
- Target Price
- NG N/A
- TVTX $23.46
- AVG Volume (30 Days)
- NG 1.3M
- TVTX 1.4M
- Earning Date
- NG 10-02-2024
- TVTX 10-31-2024
- Dividend Yield
- NG N/A
- TVTX N/A
- EPS Growth
- NG N/A
- TVTX N/A
- EPS
- NG N/A
- TVTX N/A
- Revenue
- NG N/A
- TVTX $203,447,000.00
- Revenue This Year
- NG N/A
- TVTX $62.45
- Revenue Next Year
- NG N/A
- TVTX $59.30
- P/E Ratio
- NG N/A
- TVTX N/A
- Revenue Growth
- NG N/A
- TVTX 57.08
- 52 Week Low
- NG $2.23
- TVTX $5.12
- 52 Week High
- NG $4.88
- TVTX $20.33
- Technical
- Relative Strength Index (RSI)
- NG 41.98
- TVTX 51.53
- Support Level
- NG $3.26
- TVTX $16.89
- Resistance Level
- NG $3.41
- TVTX $19.51
- Average True Range (ATR)
- NG 0.16
- TVTX 1.23
- MACD
- NG 0.00
- TVTX -0.16
- Stochastic Oscillator
- NG 27.19
- TVTX 26.69
About NG Novagold Resources Inc.
Novagold Resources Inc is a mineral exploration company engaged in the exploration and development of mineral properties. The company owns 50% of the Donlin Gold project, which is located in southwestern Alaska, approximately 20 kilometers north of the village of Crooked Creek on the Kuskokwim River.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.